【24h】

Clinic study of correlation between myeloperoxidase and acute coronary syndrome

机译:髓过氧化物酶与急性冠脉综合征相关性的临床研究

获取原文

摘要

Objective To study whether myeloperoxidase (MPO) can provide prognostic information in patients with acute coronary syndromes (ACS).Methods The study population consisted of 274 consecutive patients with ACS.All patients underwent coronary angiography which showed significant coronary artery disease and blood samples were collected at admission.Follow-ups were scheduled at 1, 3, and 6 months.The end point included cardiac death, acute myocardial infarction (MI), percutaneous or surgical revascularization.Results Patients with elevated MPO serum levels (MPO ≥ 72.2 AUU/L) were more likely to have diabetics and had a history of coronary events.Kaplan-Meier event rate curves with accumulative incidence of end point at 6-month follow-up in the MPO ≥ 72.2 AUU/L group was significantly higher than in MPO<72.2 AUU/L group.Conclusions MPO may be a powerful predictor of adverse outcome in patients with ACS.
机译:目的探讨髓过氧化物酶(MPO)能否为急性冠脉综合征(ACS)患者提供预后信息。方法研究对象为274例连续的ACS患者,所有患者均接受了冠状动脉造影检查,并显示出明显的冠状动脉疾病,并采集了血样随访时间分别为1、3和6个月,终点包括心源性死亡,急性心肌梗塞(MI),经皮或手术血运重建结果MPO血清水平升高的患者(MPO≥72.2 AUU / L MPO≥72.2 AUU / L组的6个月随访中终点累积发生率的Kaplan-Meier事件发生率曲线显着高于MPO < 72.2 AUU / L组。结论MPO可能是ACS患者不良结局的有力预测指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号